Sansheng Pharmaceutical: Achieve revenue of 17.7 billion yuan by 2025, with three new drugs consecutively approved for market launch.

LightningPacketLoss · 2026-04-01T20:25:36+00:00

Sansheng Pharmaceuticals will achieve an operating revenue of 17.7 billion yuan and a net profit of 8.48 billion yuan in 2025, representing year-on-year increases of 94.3% and 305.8%, respectively. The company is increasing R&D investment, has reached a cooperation agreement with Pfizer worth over $6 billion, strengthening its innovation pipeline and enhancing global competitiveness.

LightningPacketLoss

2026-04-01 20:25:36

Abstract generation in progress

On March 30, Sansheng Pharmaceutical released its 2025 annual performance announcement. The company’s full-year 2025 operating revenue reached RMB 177.0 billion, surpassing the RMB 10 billion mark for the first time, up 94.3% year over year; its attributable net profit to shareholders was RMB 84.8 billion, up 305.8%; its adjusted attributable net profit was RMB 84.5 billion, up 264.6%. Profitability saw a leap forward, demonstrating strong growth momentum.

In 2025, the company’s full-year R&D expenses totaled RMB 15.2 billion, up 14.6% year over year, providing solid support for advancing its innovative pipeline. By the end of 2025, the company’s financial resources rose to RMB 204.0 billion; its interest-bearing liabilities ratio fell to 9.8%; and its comprehensive financial cost delivered a positive contribution of RMB 2.3 billion,

During the reporting period, Sansheng Pharmaceutical and Pfizer reached a global licensing cooperation with a total amount exceeding USD 6 billion. The deal brought in a USD 1.4 billion upfront payment and USD 100 million in equity collaboration, setting a new highest record for China’s innovative drug outbound offerings by upfront payment. The core product Tiberio®—with a new indication—was successfully approved. Three new drugs were approved for launch in succession, while three products entered the NDA stage. This builds a matrix of innovative pipelines across multiple therapeutic areas, further strengthening the company’s global competitiveness and advantages in core treatment areas, and injects strong momentum into the company’s high-quality development.

(Sansheng Pharmaceutical announcement)

(Editor: Yang Yan, Lin Chen)

Keywords:

                                                            Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.